Maxim Research - New York, page-4

Absolutely they are what actually matter.

Say, how do you reckon they're gonna get to the trial results?

Mmmmhmmmm - money.

Where'd you reckon that moneys gonna come from.

Partnerships, shareholders and equity finance....

Now, how many partnerships have they signed? Given this CR wasn't fully subscribed how many more times you think they can out their hand out? And if they dilute SH's further by going back to the equity finance how long you reckon shareholders are gonna hang around....

So yes, focus on the destination. But let's also wonder HTF we gonna get there. That would seem prudent, no?

Of all people, Michael Spooner should know what happens to companyies who run out of money before they get the trial results. Granted it was after his watch, but ventracor continues to be a cautionary tale for trials companies thinking money grows on trees.